Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus PT from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average recommendation of “Buy” by the seven analysts that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $11.00.

Several research analysts recently issued reports on the stock. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price for the company. Leerink Partners upped their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, December 20th.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AQST. Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $27,000. nVerses Capital LLC acquired a new position in shares of Aquestive Therapeutics during the third quarter valued at approximately $28,000. The Manufacturers Life Insurance Company purchased a new position in shares of Aquestive Therapeutics in the second quarter valued at approximately $76,000. Financial Advocates Investment Management boosted its stake in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares during the last quarter. Finally, Harvey Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics during the third quarter worth approximately $88,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $3.52 on Friday. The stock’s fifty day moving average price is $4.61 and its 200 day moving average price is $4.09. Aquestive Therapeutics has a 1 year low of $1.95 and a 1 year high of $6.23. The company has a market cap of $320.95 million, a price-to-earnings ratio of -7.82 and a beta of 2.62.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same period last year, the business earned ($0.03) earnings per share. Research analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.